Temozolomide and Its Effect on DNA Repair Enzyme in Blood Cells
Author Information
Author(s): S.M. Lee, N. Thatcher, D. Crowther, G.P. Margison
Primary Institution: Paterson Institute for Cancer Research, Christie Hospital NHS Trust
Hypothesis
Does temozolomide deplete the activity of 06-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells?
Conclusion
Temozolomide significantly depletes the activity of 06-alkylguanine-DNA alkyltransferase in blood cells over a treatment period.
Supporting Evidence
- ATase levels were significantly reduced within 4 hours of the first dose of temozolomide.
- The median nadir of ATase depletion was 52.9% of pretreatment levels.
- A strong correlation (r = 0.97) was found between pretreatment ATase levels and the extent of depletion.
Takeaway
Temozolomide is a medicine that helps treat cancer by reducing a specific enzyme in blood cells that can make cancer cells resistant to treatment.
Methodology
The study measured the activity of the enzyme in blood samples from patients before and after treatment with temozolomide.
Limitations
The study only included a small number of patients and did not assess tumor tissue.
Participant Demographics
Patients had metastatic melanoma, with a range of ages and both sexes represented.
Statistical Information
P-Value
0.97
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website